CN113018300B - 用于治疗神经病症的方法 - Google Patents

用于治疗神经病症的方法

Info

Publication number
CN113018300B
CN113018300B CN202110348688.2A CN202110348688A CN113018300B CN 113018300 B CN113018300 B CN 113018300B CN 202110348688 A CN202110348688 A CN 202110348688A CN 113018300 B CN113018300 B CN 113018300B
Authority
CN
China
Prior art keywords
rats
dose
day
administered
mapk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110348688.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113018300A (zh
Inventor
约翰·贾汉吉尔·阿拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIP Pharma LLC
Original Assignee
EIP Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EIP Pharma LLC filed Critical EIP Pharma LLC
Publication of CN113018300A publication Critical patent/CN113018300A/zh
Application granted granted Critical
Publication of CN113018300B publication Critical patent/CN113018300B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202110348688.2A 2014-07-09 2015-07-08 用于治疗神经病症的方法 Active CN113018300B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462022586P 2014-07-09 2014-07-09
US62/022,586 2014-07-09
CN201580037336.8A CN106659723A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
PCT/US2015/039539 WO2016007616A1 (en) 2014-07-09 2015-07-08 Methods for treating neurologic disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580037336.8A Division CN106659723A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Publications (2)

Publication Number Publication Date
CN113018300A CN113018300A (zh) 2021-06-25
CN113018300B true CN113018300B (zh) 2025-11-25

Family

ID=55064826

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110348688.2A Active CN113018300B (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN202110783304.XA Pending CN114010641A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN201580037336.8A Pending CN106659723A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110783304.XA Pending CN114010641A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN201580037336.8A Pending CN106659723A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Country Status (5)

Country Link
US (1) US9579322B2 (enExample)
EP (1) EP3166610B1 (enExample)
JP (1) JP6660369B2 (enExample)
CN (3) CN113018300B (enExample)
WO (1) WO2016007616A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018300B (zh) 2014-07-09 2025-11-25 爱普制药有限责任公司 用于治疗神经病症的方法
KR102891465B1 (ko) 2015-10-26 2025-11-25 이아이피 파마 엘엘씨 뇌졸중으로부터의 회복을 위한 방법 및 조성물
WO2017185073A1 (en) * 2016-04-21 2017-10-26 Eip Pharma, Llc Compositions and methods for treating dementia
WO2019056003A1 (en) 2017-09-18 2019-03-21 Eip Pharma, Llc CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745)
UY37918A (es) 2017-10-05 2019-04-30 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10653695B2 (en) * 2018-03-12 2020-05-19 Eip Pharma, Llc Pharmaceutical formulations of neflamapimod
US12220412B2 (en) * 2018-11-20 2025-02-11 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
EP3986856A4 (en) 2019-06-18 2023-07-19 Opiant Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANNABINOID HYPEREMESSI SYNDROME WITH A CANNABINOID RECEPTOR ANTAGONIST
AU2020295410A1 (en) * 2019-06-18 2022-01-20 Indivior Uk Limited Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
WO2021011432A1 (en) 2019-07-12 2021-01-21 Eip Pharma, Inc. Compositions and methods for treating dementia with lewy bodies
CN116801887A (zh) * 2020-11-06 2023-09-22 Eip制药公司 治疗神经退行性疾病的步态功能障碍
CN113616795B (zh) * 2021-08-31 2023-06-20 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
IL311960A (en) * 2021-11-05 2024-06-01 Eip Pharma Llc Treatment of a selective population of patients suffering from dementia with Lewy bodies
US20240358962A1 (en) * 2023-04-27 2024-10-31 Remepy Health Ltd Digital therapeutics for improved immune function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103842362A (zh) * 2011-05-09 2014-06-04 爱普制药有限责任公司 用于治疗阿尔茨海默氏病的组合物和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
CA2558439A1 (en) 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
US20050203111A1 (en) 2004-03-12 2005-09-15 Vvii Newco 2003, Inc. Compositions and methods for preventing and treating skin and hair conditions
KR101329112B1 (ko) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
WO2008002465A2 (en) 2006-06-23 2008-01-03 The Feinstein Institute For Medical Research INHIBITORS OF Aβ AND SYNUCLEIN AGGREGATION
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
MX2013011518A (es) * 2011-04-08 2014-06-04 Afraxis Holdings Inc 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer.
CN113018300B (zh) 2014-07-09 2025-11-25 爱普制药有限责任公司 用于治疗神经病症的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103842362A (zh) * 2011-05-09 2014-06-04 爱普制药有限责任公司 用于治疗阿尔茨海默氏病的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rational Design of Novel Potential p38α MAPK Inhibitors with Drug-like Properties Using Pharmacophore and Similarity-based Virtual Screenin Procedures;F. R. Pinsetta等;《Current Bioactive Compounds》;第9卷(第1期);第3-13页 *

Also Published As

Publication number Publication date
JP6660369B2 (ja) 2020-03-11
WO2016007616A1 (en) 2016-01-14
EP3166610B1 (en) 2022-11-02
CN114010641A (zh) 2022-02-08
US9579322B2 (en) 2017-02-28
JP2017519807A (ja) 2017-07-20
CN113018300A (zh) 2021-06-25
EP3166610A4 (en) 2017-11-29
CN106659723A (zh) 2017-05-10
EP3166610A1 (en) 2017-05-17
US20160008364A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
CN113018300B (zh) 用于治疗神经病症的方法
RU2338533C1 (ru) СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
CN103842362B (zh) 用于治疗阿尔茨海默氏病的组合物和方法
Bockaert et al. mTOR in brain physiology and pathologies
TWI582079B (zh) σ配體類於與第２型糖尿病有關之疼痛上之用途
JP2010511616A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
JP2022532379A (ja) 神経変性および代謝障害の処置のための化合物
AU2007229322A1 (en) Method of treatment or prophylaxis inflammatory pain
US20220047568A1 (en) Neuroprotective cb2 receptor agonists
KR102891465B1 (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
US9427439B1 (en) Methods and compositions for recovery from stroke
JP2010531854A (ja) 抗アミロイド剤としてのピレンゼピンおよびその誘導体
KR20170106485A (ko) 요산 또는 통풍 질환의 예방 또는 치료
JP6629464B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ
JP6606298B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
Wallach et al. Receptor targets in Alzheimer’s disease drug discovery
HK40068517A (en) Methods for treating neurologic disorders
JP7443255B2 (ja) 疼痛使用のためのｃｈ２４ｈ阻害剤
US6987105B2 (en) Synthesis and use of thienotriazolodiazepines
Yaari et al. Cognitive enhancers and treatments for Alzheimer's disease
WO2025229051A1 (en) Use of atr inhibitors in combination with antiandrogen agent
EA042685B1 (ru) Новые применения чистого антагониста 5-ht6 рецептора
HK40019123A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK1230184B (en) Compositions and methods for treating alzheimer's disease
HK1260485A1 (en) Methods and compositions for recovery from stroke

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant